Table 2.

Risk of bias in a randomized trial and non-randomized studies of anti-Ebola therapies

Agent Citation	Bias arising from the randomization process	Bias due to confounding	Bias in selection of participants	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing outcome data	Bias in outcomes measurement	Bias in selection of results reported	Overall risk of bias
Randomized clinical trial
ZMapp PREVAIL II Writing Group, 2016 [24]	Low	N/A	N/A	N/A	Some concerns	Low	Low	Low	Low
Non-randomized single-arm intervention study with concurrent controls
TKM-130803 Dunning et al., 2016 [25]	N/A	Moderate	Moderate	Low	Low	Low	Low	Low	Moderate
Convalescent whole blood Sahr et al., 2017 [26]	N/A	Moderate	Low to moderate	Moderate	Moderate	Low	Low	Low	Moderate
Interferon β-1a Konde et al., 2017 [27]	N/A	Moderate to serious	Low	Moderate to low	Low	Low	Low	Low	Moderate
Non-randomized, single-arm, intervention study with historical control
Convalescent plasma van Griensven et al., 2016 [28]	N/A	Serious	Moderate	Low	Low	Low	Low	Low	Moderate
Favipiravir Sissoko et al., 2016 [29]	N/A	Serious to critical	Low	Low	Moderate	Low	Low	Low	Moderate
Favipiravir Bai et al., 2016 [30]	N/A	Serious	Moderate	Moderate	Moderate	Moderate	Moderate	Low	Moderate
Non-randomized single-arm intervention study without controls
Brincidofovir Dunning et al., 2016 [31]	N/A	Critical	Low to moderate	Low	Moderate	Low	Low	Low	Moderate
Retrospective cohort study
Artesunate-amodiaquine Gignoux et al., 2016 [32]	N/A	Moderate to serious	Moderate	Moderate	Low	Low	Low	Low	Moderate

Abbreviations: N/A not applicable